2. Search Result
Search Result
Results for "

p97 mutant D649A/T688A

" in MedChemExpress (MCE) Product Catalog:

1326

Inhibitors & Agonists

4

Bibliotecas de Screening

15

Fluorescent Dyes

19

Biochemical Assay Reagents

39

Peptides

2

MCE Kits

12

Inhibitory Antibodies

47

Natural
Products

8

Recombinant Proteins

38

Isotope-Labeled Compounds

17

Antibodies

27

Click Chemistry

8

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-156819
    Zoldonrasib
    5 Publications Verification

    RMC-9805; KRAS G12D inhibitor 18

    		 Ras Apoptosis Cancer
    Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer .
    Zoldonrasib
  • HY-153724
    BI-2865
    10+ Cited Publications

    		 Ras Cancer
    BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM) .
    BI-2865
  • HY-110078
    Eeyarestatin I
    10+ Cited Publications

    		 p97 Apoptosis Cancer
    Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I inhibits Sec61 translocon. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I interferes at a step prior to proteasomal degradation. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects .
    Eeyarestatin I
  • HY-12861
    CB-5083
    45+ Cited Publications

    		 p97 Cancer
    CB-5083 is a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase/VCP. CB-5083 selectively inhibits p97 through its D2 site with the IC50 of 11 nM .
    CB-5083
  • HY-15713
    NMS-873
    15+ Cited Publications

    		 p97 Cancer
    NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC50 value of 30 nM.
    NMS-873
  • HY-123636
    UPCDC-30245

    		p97 Cancer
    UPCDC-30245 is an allosteric p97 inhibitor with an IC50 of approximately 27 nM . UPCDC-30245 inhibits the p97 mutant N660K similar to wild type (WT; IC50=300 nM) and shows 3-fold resistance for p97 mutant T688A . UPCDC-30245 can be used in the research of cancer .
    UPCDC-30245
  • HY-114226
    Olutasidenib
    3 Publications Verification

    FT-2102

    		 Isocitrate Dehydrogenase (IDH) Inflammation/Immunology Cancer
    Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
    Olutasidenib
  • HY-15945
    DBeQ
    5+ Cited Publications

    JRF 12

    		 p97 Autophagy Apoptosis Cancer
    DBeQ is a selective, potent, reversible, and ATP-competitive p97 inhibitor, with an IC50 value of 1.5 μM and 1.6 μM for p97(wt) and p97(C522A), respectively; DBeQ also inhibits Vps4 with an IC50 of 11.5 μM.
    DBeQ
  • HY-19795
    ML240
    5 Publications Verification

    		 p97 Cancer
    ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML240
  • HY-128724
    CB-5339
    2 Publications Verification

    		 p97 Cancer
    CB-5339 is an oral activity potent p97 inhibitor with an IC50 <30 nM. CB-5339 can be used for leukemia research . CB-5339 extracted from WO2015109285A1 compound FF07.
    CB-5339
  • HY-123872
    MSC1094308
    1 Publications Verification

    		 p97 Cancer
    MSC1094308 is a non-competitive and reversible VPS4B/p97 (VCP) (I/II type AAA ATPase) allosteric inhibitor, with IC50 values of 0.71 μM and 7.2 μM for VPS4B and p97, respectively . MSC1094308 inhibits the D2 ATPase activity by binding to a agentable hotspot of p97. MSC1094308 can be used in study of cancer .
    MSC1094308
  • HY-141640
    MS154

    		PROTACs EGFR Cancer
    MS154 is a first-in-class E3 ligase cereblon-recruited EGFR degrader with Kd values of 1.8 nM and 3.8 nM for EGFR WT and EGFR L858R mutant, respectively. MS154 potently induces degradation of mutant, but not wild-type, EGFR in cancer cell lines in an E3 ligase-dependent manner. MS154 exhibits anticancer effects against lung cancer (blue: E3 ligase ligand (HY-103596); black: linker (HY-W096167); pink: EGFR ligand (HY-168305)) .
    MS154
  • HY-19797A
    ML241 hydrochloride

    		p97 Cancer
    ML241 hydrochloride is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML241 hydrochloride
  • HY-137342
    SB1-G-187

    		PROTACs Src IRAK Bcr-Abl MAP4K Cyclin G-associated Kinase (GAK) CDK Cancer
    SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, IRAK1 and LYN. SB1-G-187 induces degradation of target kinases via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker) .
    SB1-G-187
  • HY-129545
    DS-1001b
    2 Publications Verification

    		 Isocitrate Dehydrogenase (IDH) Cancer
    DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity .
    DS-1001b
  • HY-12475
    Mutant IDH1-IN-1
    2 Publications Verification

    Agios 135

    		 Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-1 (Agios 135) is a selective mutant IDH1 inhibitor with activity against both IDH1 R132H and IDH1 R132C. Mutant IDH1-IN-1 reduces the level of 2-hydroxyglutarate (2-HG), stabilizes mutant IDH1 protein, and restores blocked monocyte differentiation. Mutant IDH1-IN-1 can be used in tumor-related research .
    Mutant IDH1-IN-1
  • HY-11067
    WHI-P97
    1 Publications Verification

    		 JAK Inflammation/Immunology
    WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .
    WHI-P97
  • HY-138233
    KUS121

    		p97 Neurological Disease Inflammation/Immunology
    KUS121, a valosin-containing protein (VCP, p97) modulator with significant neuroprotective effects, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress .
    KUS121
  • HY-15714
    NMS-859
    1 Publications Verification

    		 p97 Cancer
    NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
    NMS-859
  • HY-145594
    Safusidenib
    2 Publications Verification

    AB-291; DS-1001

    		 Isocitrate Dehydrogenase (IDH) Cancer
    Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma . Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively .
    Safusidenib
  • HY-W111581
    Copper(II) diethyldithiocarbamate
    1 Publications Verification

    Diethyldithiocarbamic acid copper salt

    		 Apoptosis Caspase Cancer
    Copper(II) diethyldithiocarbamate (Diethyldithiocarbamic acid copper salt) is a Copper(II) and diethyldithiocarbamate coordination polymer. Copper(II) diethyldithiocarbamate binds tightly to NPL4 and induces its aggregation, disrupting the p97-NPL4-UFD1 pathway. Copper(II) diethyldithiocarbamate causes ubiquitinated proteins accumulation and impairs waste proteins degradation, thus resulting in cell apoptosis. Copper(II) diethyldithiocarbamate inhibits tumor growth in MDA-MB-231 xenograft mice models. Copper(II) diethyldithiocarbamate can be used for the research of cancer, such as breast cancer .
    Copper(II) diethyldithiocarbamate
  • HY-13984
    NT-1
    1 Publications Verification

    EGFR mutant-IN-3

    		 EGFR ERK Apoptosis Drug Derivative Cancer
    NT-1 (EGFR mutant-IN-3) is a potent mutant EGFR inhibitor and an analog of Osimertinib (HY-15772). This mutant EGFR inhibitor suppresses FGFR WT with an IC50 of 0.4 nM. NT-1 also inhibits EGFR L858R, EGFR Exon 19 deletion and EGFR T790M. NT-1 exerts deeper inhibition on p-EGFR and p-ERK, and induces tumor cell apoptosis. NT-1 can be used in colorectal cancer research .
    NT-1
  • HY-D1056C5
    Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant)

    LPS, from Salmonella enterica (Serotype minnesota Re 595 (Re mutant))

    		 Toll-like Receptor (TLR) Bacterial Inflammation/Immunology
    Lipopolysaccharides (LPS), from S. enterica (Salmonella enterica) serotype minnesota Re 595 (Re mutant) is prepared from Salmonella enterica strain Re 595 (Re mutant). The structure in the LPS of strain Re 595 was shown to induce secretion and aggregation in human platelets .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant)
  • HY-139606
    VCP/p97 inhibitor-1

    		p97 Cancer
    VCP/p97 inhibitor-1 is a potent inhibitor of VCP/p97 (also called Cdc48, CDC-. 48, or Ter94) with an IC50 of 54.7 nM. VCP/p97 inhibitor-1 causes the dysregulation of protein homeostasis and disturbs the degradation of misfolded polypeptides by the ubiquitin-proteasome system (UPS) .
    VCP/p97 inhibitor-1
  • HY-145759
    Mutant p53 modulator-1
    1 Publications Verification

    		 MDM-2/p53 Cancer
    Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B) .
    Mutant p53 modulator-1
  • HY-E70884
    Endoglycosidase S2 (D184M mutant)

    EndoS2 D184M

    		 Glycosidase Others
    Endoglycosidase S2 (D184M mutant) (EndoS2 D184M) is a mutant endoglycosidase. Endoglycosidase S2 (D184M mutant) promotes the transfer of glyco-oxazoline donors with defined glycoforms to the Fc region of IgG antibodies .
    Endoglycosidase S2 (D184M mutant)
  • HY-13972
    Mutant IDH1 inhibitor
    2 Publications Verification

    		 Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
    Mutant IDH1 inhibitor
  • HY-174984
    VCP/p97 IN-3

    		p97 Caspase p62 Cancer
    VCP/p97 IN-3 is a VCP/p97 allosteric inhibitor. VCP/p97 IN-3 shows the inhibitory activity against the VCP proteins with an IC50 of 9 nM and the mutant VCP proteins with IC50 of 12 nM (N660K) and 19 nM (V474A/D649A). VCP/p97 IN-3 increases K48-linked ubiquitination and the level of cleaved caspase-3. VCP/p97 IN-3 activates ER-stress and the UPR. VCP/p97 IN-3 inhibits tumor growth in RPMI-8226 cell subcutaneous xenograft mouse models. VCP/p97 IN-3 can be used for the study of multiple myeloma .
    VCP/p97 IN-3
  • HY-19797
    ML241

    		p97 Cancer
    ML241 is a potent, selective and competitive p97 ATPase inhibitor with an IC50 of 0.11 μM. ML241 can be used for the research of cancer .
    ML241
  • HY-148122
    NW 1028

    		p97 Cancer
    NW 1028 is a potent VCP/p97 inhibitor. NW 1028 targets the ND1L domain of p97 and inhibits the degradation of a p97-dependent reporter. NW 1028 has good binding affinity with Kd values of 100 and 285 nM for ND1L and full length p97, respectively. NW 1028 has the function of regulating the mitotic spindle of cells .
    NW 1028
  • HY-131312
    Crelosidenib

    LY3410738; mutant IDH1-IN-6

    		 Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes .
    Crelosidenib
  • HY-124776
    NPD8733

    		p97 Cancer
    NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration. NPD8733 specifically binds to valosin-containing protein (VCP)/p97, a member of the ATPase-associated with diverse cellular activities (AAA+) protein family. NPD8733 has the potential for the research of cancer diseases .
    NPD8733
  • HY-153974
    BBT-176

    		EGFR Cancer
    BBT-176 is an orally effective EGFR inhibitor. BBT-176 has inhibitory activity against multiple EGFR C797S mutant cell lines. BBT-176 is commonly used in cancer research .
    BBT-176
  • HY-124761
    Poloppin

    		Polo-like Kinase (PLK) Autophagy Mitosis Cancer
    Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .
    Poloppin
  • HY-77113
    B-Raf IN 11

    		Raf Cancer
    B-Raf IN 11 is a B-Raf V600E mutant kinase inhibitor with an IC50 of 76 nM, and exhibits an IC50 of 238 nM against wild-type B-Raf kinase. B-Raf IN 11 inhibits the kinase activities of B-Raf V600E mutant and wild-type B-Raf kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .
    B-Raf IN 11
  • HY-179257
    p97-IN-2

    		p97 Cancer
    p97-IN-2 (Compound 14) is a p97 ATPase (IC50 = 0.6 μM) inhibitor. p97-IN-2 can inhibit cell proliferation, such as HCT15 (IC50 = 1.1 μM) and SW403 (IC50 = 0.8 μM) cells. p97-IN-2 can be used for cancer research .
    p97-IN-2
  • HY-174844
    p97-IN-1

    		p97 Cancer
    p97-IN-1 is an orally active p97 inhibitor (IC50 = 26 nM). p97-IN-1 can significantly inhibit the proliferation of tumor cells. p97-IN-1 can be used for research on acute myeloid leukemia (AML) .
    p97-IN-1
  • HY-18717
    Mutant IDH1-IN-2
    2 Publications Verification

    		 Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
    Mutant IDH1-IN-2
  • HY-174847
    VCP/p97 IN-2

    		p97 Cancer
    VCP/p97 IN-2 (Compound V13) is a VCP/p97 inhibitor with IC50 of 32 nM for p97. VCP/p97 IN-2 has excellent antitumor activities and significantly inhibits tumor growth in Molm-13 xenograft mice model. VCP/p97 IN-2 can be used for acute myeloid leukemia (AML) research .
    VCP/p97 IN-2
  • HY-E70883
    Endoglycosidase S (D233Q mutant)

    EndoS D233Q

    		 Glycosidase Others
    Endoglycosidase S (D233Q mutant) (EndoS D233Q) is a mutant endoglycosidase, which catalyzes the glycosylation of Trastuzumab (HY-P9907)-GlcNAc with the functionalized, non-natural glycans to give glycosylated monoclonal Abs (mAbs) carrying two glycans each functionalized with two reaction handles .
    Endoglycosidase S (D233Q mutant)
  • HY-E70879
    Endoglycosidase M (N175Q mutant)

    EndoM N175Q

    		 Glycosidase Others
    Endoglycosidase M (N175Q mutant) (EndoM N175Q) can transfer natural N-glycans or oxazoline N-glycans to any peptide or protein with a GlcNAc residue to form a β1-4-glycosidic linkage. Endoglycosidase M (N175Q mutant) is a useful tool in the synthesis of homogeneous glycopeptides and glycoproteins .
    Endoglycosidase M (N175Q mutant)
  • HY-153767
    PK095

    		MDM-2/p53 Cancer
    PK095 is a p53 mutant stabilizer. PK095 can be used for research of cancer .
    PK095
  • HY-149464
    ARN22089

    		Ras Cancer
    ARN22089 is a oral active novel class of trisubstituted pyrimidine, blocks the interaction of CDC42 GTPases with specific downstream effectors. ARN22089 blocks tumor growth in BRAF mutant mouse melanoma model .
    ARN22089
  • HY-19634
    YK-3-237
    1 Publications Verification

    		 Sirtuin Cancer
    YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells .
    YK-3-237
  • HY-126905
    ZMC3

    NSC328784

    		 Reactive Oxygen Species (ROS) Cancer
    ZMC3 (NSC328784) is a zinc chelator. ZMC3 shows Zinc metallochaperone properties. ZMC3 shows enhanced sensitivity in p53-R175H mutant cells. ZMC3 increases the cell ROS level .
    ZMC3
  • HY-168005
    NSC799462

    		p97 ATP Synthase Cancer
    NSC799462 is a triazole inhibitor of p97 ATPase. NSC799462 inhibits p97 ATPase activity (IC50 = 15 nM) by binding to a specific site on p97 and causing local changes in the p97 structure .
    NSC799462
  • HY-19795R
    ML240 (Standard)

    		p97 Cancer
    ML240 (Standard) is the analytical standard of ML240. This product is intended for research and analytical applications. ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML240 (Standard)
  • HY-126298
    RAF mutant-IN-1

    		Raf Cancer
    RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAF V600E and B-RAF WT, respectively .
    RAF mutant-IN-1
  • HY-155026
    UPCDC30766

    		p97 Cancer
    UPCDC30766 is a potent allosteric inhibitor of p97 (IC50 of 12 nM; EC50 of 0.23 μM in cells). UPCDC30766 can be used for the research of colon cancer .
    UPCDC30766
  • HY-131067
    EMI56

    		EGFR Cancer
    EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants .
    EMI56

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: